PT  - JOURNAL ARTICLE
AU  - NAKANISHI, KEITA
AU  - SAKAKURA, NORIAKI
AU  - MATSUI, TAKUYA
AU  - UENO, HARUSHI
AU  - NAKADA, TAKEO
AU  - OYA, YUKO
AU  - SHIMIZU, JUNICHI
AU  - HIDA, TOYOAKI
AU  - HOSODA, WAKI
AU  - KURODA, HIROAKI
TI  - Clinicopathological Features, Surgical Outcomes, Oncogenic Status and PD-L1 Expression of Pulmonary Pleomorphic Carcinoma
AID  - 10.21873/anticanres.13782
DP  - 2019 Oct 01
TA  - Anticancer Research
PG  - 5789--5795
VI  - 39
IP  - 10
4099  - http://ar.iiarjournals.org/content/39/10/5789.short
4100  - http://ar.iiarjournals.org/content/39/10/5789.full
SO  - Anticancer Res2019 Oct 01; 39
AB  - Background/Aim: Pulmonary pleomorphic carcinoma (PPC) is rare, and few studies have reported its features. We assessed the clinicopathological features, surgical outcomes, oncogenic status and programmed death-ligand 1 (PD-L1) expression of PPC. Patients and Methods: We retrospectively reviewed data from 22 consecutive patients who underwent resection of PPC between 2007 and 2017. Results: The predominant tissue type of the epithelial component was adenocarcinoma in 15 patients (68%) and the others in 7 patients (32%), and the 3-year disease-free survival rate tended to be better in patients with an adenocarcinoma component compared to patients with another component (40.0% vs. 17.1%, p=0.059). PD-L1 expression was observed in all eight tumors whose PD-L1 status could be examined and high PD-L1 expression (≥50%) was frequent (5/8, 63%). Conclusion: A predominant adenocarcinoma epithelial component in PPC might be associated with better survival outcomes and high PD-L1 expression might be frequent in PPC.